Lansforsakringar Fondforvaltning Ab (Publ) Argenx Se Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $15.9 Billion
- Q1 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Argenx Se stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 362 shares of ARGX stock, worth $196,258. This represents 0.0% of its overall portfolio holdings.
Number of Shares
362
Previous 434
16.59%
Holding current value
$196,258
Previous $266,000
19.55%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
498Shares Held
28.5MCall Options Held
330KPut Options Held
286K-
Price T Rowe Associates Inc Baltimore, MD5.38MShares$2.92 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$1.51 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.14MShares$1.16 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.94MShares$1.05 Billion0.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$670 Million11.83% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $30B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...